#Research institutes in Biosimilar market US

[kenresearch1]

Biosimilars Unleashed: The Future of Healthcare in the US

Buy Now

What is the Size of US Biosimilar Industry?

US Biosimilar Market is expected to grow at a CAGR of ~ % between 2017-2022 and is expected to reach ~USD Bn by 2028. Biosimilars enhance patient access to essential treatments, especially in therapies with high demand, like oncology, by providing more affordable options. Additionally, Growing evidence of biosimilars' comparable efficacy and safety fosters trust among healthcare professionals, driving adoption.

Click here to Download a sample Report

Biosimilars offer cost savings compared to originator biologics, addressing the need for affordable healthcare solutions in the face of rising medical costs. Favorable regulatory frameworks, like the BPCIA, streamline biosimilar approval processes, encouraging manufacturers to invest in development.

Furthermore, The expiration of patents for numerous reference biologics creates opportunities for biosimilar entry, leading to increased competition and market expansion. Pharmaceutical companies are investing in biosimilar R&D and production, expanding the pipeline and market availability. Supportive healthcare policies and reimbursement models incentivize biosimilar adoption, creating a favorable environment for market growth.

US Biosimilar Market by drug class

The US Biosimilar market is segmented by Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory agents and Others. Based on drug class, Monoclonal Antibodies segment dominates the bio similar market in 2022.

Monoclonal antibodies have diverse applications across various therapeutic areas. From cancer treatment to autoimmune diseases, biosimilar Mabs addressed a wide range of medical needs, leading to a broad and growing market. Biosimilars, with their potential for cost savings while maintaining comparable efficacy and safety, gained significant attention as viable alternatives.

US Biosimilar Market by application

In US Biosimilar market, they are segmented by application into Oncology, Blood disorders, Chronic diseases and autoimmune conditions and Others. On the basis of application, Oncology segment was the dominant in 2022.

The increasing prevalence of cancer and the high cost of traditional biologics used in oncology treatment have created a strong incentive for the adoption of biosimilars. Biosimilars offer the potential to provide similar therapeutic outcomes at a lower cost, making them an attractive option for both healthcare providers and patients.

Additionally, the rigorous clinical trials and regulatory processes that biosimilars undergo to gain approval provide reassurance to healthcare professionals and patients regarding their safety and efficacy. This has led to increased acceptance and adoption of biosimilars in oncology.

US Biosimilar by Region

The US Biosimilar market is segmented by Region into North, East, West and South. In 2022, the dominance region is North region in US Biosimilar market.

The North region benefits from a concentration of healthcare providers and academic institutions that are at the forefront of adopting and integrating biosimilars into their treatment protocols. These institutions are more likely to have the expertise to evaluate and incorporate biosimilars effectively, driving their adoption among healthcare professionals and patients.

Click here to Download a Custom Report

Competition Scenario in US Biosimilar Market

The US biosimilar market has witnessed an evolving competitive landscape, with several key players competing for market share. Prominent pharmaceutical companies such as Amgen, Pfizer, Sandoz (Novartis), and Boehringer Ingelheim have been actively involved in developing and marketing biosimilar products. These established players have utilized their expertise in biologics and significant resources to navigate the regulatory landscape and compete effectively.

The competition in the US biosimilar market is characterized by a balance between established pharmaceutical giants and emerging biotech companies. While the major players possess the advantage of resources and experience, smaller biotech firms are also contributing to the market with innovative approaches and niche biosimilar offerings.

What is the Expected Future Outlook for the Overall US Biosimilar Market?

The US Biosimilar market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Billion by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. The US biosimilar market is likely to experience significant growth in the coming years, driven by several factors. Biosimilars are biologic drugs that are highly similar to already approved reference biologics. They offer potential cost savings, increased competition, and improved patient access to crucial treatments.

Firstly, the regulatory environment is becoming more favorable for biosimilars. The Biologics Price Competition and Innovation Act (BPCIA) established a pathway for biosimilar approval in the US, allowing for a smoother regulatory process. As more biosimilars receive approval, competition in the market is expected to intensify.

Secondly, patents for several blockbuster biologics are expiring or have already expired. This creates opportunities for biosimilar manufacturers to enter the market with more affordable alternatives, offering healthcare systems and patients a choice in treatment options.

Thirdly, as healthcare costs continue to rise, biosimilars present an attractive solution for reducing expenses. Their potential to offer cost savings without compromising therapeutic efficacy could lead to increased adoption by healthcare providers, insurers, and patients alike.

Physician and patient education are crucial, as misconceptions about biosimilars' safety and effectiveness might hinder their adoption. Additionally, legal and market access barriers, including patent litigation and complex distribution systems, could slow down the growth of the biosimilar market.

The biosimilar market witness consolidation as larger pharmaceutical companies acquire or partner with smaller biotech firms to bolster their biosimilar portfolios. This will lead to more resources being devoted to biosimilar development and marketing. Changes in healthcare policies, such as reimbursement models and value-based care initiatives, can influence the biosimilar market's growth. Favourable policies that incentivize biosimilar adoption drives their market growth.

[healthcare-skyquest]

Biosimilars Market: Driving Affordable Healthcare Solutions

The Biosimilars market has become a significant player in modern healthcare, offering cost-effective alternatives to biologics. As the demand for affordable therapeutic options rises, the market for biosimilars is gaining substantial momentum. This article delves into the market trends, segmentation, growth drivers, and leading companies in the biosimilars industry, providing crucial insights for decision-makers.

Market Overview

According to SkyQuest's Biosimilars Market report, the global market is currently valued at USD 27.30 billion in 2023, with a projected CAGR of 16.4% over the forecast period. The market's expansion is fueled by patent expirations of key biologics, increasing prevalence of chronic diseases, and a growing emphasis on cost-efficient healthcare solutions.

Request Your Free Sample: - https://www.skyquestt.com/sample-request/biosimilars-market

Market Segmentation

By Product Type:

Recombinant Non-Glycosylated Proteins: Used in the treatment of diseases such as diabetes and cancer.

Recombinant Glycosylated Proteins: Common in oncology and autoimmune disease therapies.

Peptides: An emerging class used for metabolic diseases and cancer treatment.

By Application:

Oncology: High demand for biosimilars due to the rising incidence of cancers and the need for affordable treatments.

Chronic Diseases: Biosimilars for diabetes, arthritis, and cardiovascular diseases are critical for cost-effective long-term care.

Autoimmune Diseases: Increasing prevalence of conditions like rheumatoid arthritis and multiple sclerosis is driving the demand for biosimilars.

Infectious Diseases: Expansion of biosimilars in this sector due to the global burden of infections.

By Manufacturing Type:

In-House Manufacturing: Pharmaceutical companies developing their own biosimilars to maintain control over production.

Contract Manufacturing: Outsourcing production to specialized third-party manufacturers for efficiency and scalability.

By End-User:

Hospitals and Clinics: Major centers for biosimilars administration.

Pharmaceutical Companies: Driving the production and distribution of biosimilars.

Research Institutes: Key players in the innovation and clinical trials of biosimilars.

Key Growth Drivers

Patent Expirations of Biologics: As patents for major biologic drugs expire, the market opens up for biosimilar development.

Rising Healthcare Costs: Increasing demand for cost-effective alternatives to expensive biologic therapies.

Chronic Disease Prevalence: Growing rates of cancer, diabetes, and autoimmune diseases are spurring demand for biosimilars.

Government Initiatives: Regulatory frameworks supporting the approval and adoption of biosimilars.

Read More at: - https://www.skyquestt.com/report/biosimilars-market

Leading Companies in the Market

SkyQuest’s Biosimilars Market report highlights key players driving innovation and expansion, including:

Pfizer Inc.

Novartis AG (Sandoz)

Amgen Inc.

Samsung Bioepis

Biocon

Celltrion Healthcare

Teva Pharmaceuticals

Mylan N.V.

Fresenius Kabi

Hoffmann-La Roche Ltd

Challenges and Opportunities

The biosimilars market faces hurdles such as complex manufacturing processes and regulatory challenges. However, the growing acceptance of biosimilars by healthcare providers, coupled with increasing investments in biosimilar R&D, presents significant opportunities for market players to innovate and expand.

Take Action Now: Secure Your Report Today - https://www.skyquestt.com/buy-now/biosimilars-market

Future Outlook

As healthcare systems worldwide strive to reduce costs without compromising care quality, the biosimilars market is poised for strong growth. Companies that prioritize technological advancements, navigate regulatory frameworks efficiently, and focus on patient access will thrive in this evolving market.

The biosimilars market is shaping the future of affordable healthcare. With increasing demand for cost-effective treatments, decision-makers must keep pace with the trends and opportunities in this dynamic sector. For more comprehensive insights and strategic recommendations, consult SkyQuest’s in-depth Biosimilars Market report.

[amrutatbrc1]

Rheumatology Therapeutics Market 2024 : Size, Growth Rate, Business Module, Product Scope, Regional Analysis And Expansions 2033

The Rheumatology Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Rheumatology Therapeutics Market: https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

According to The Business Research Company’s Rheumatology Therapeutics Global Market Report 2024, The rheumatology therapeutics market size is expected to see steady growth in the next few years. It will grow to $51.42 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to the shift towards personalized medicine approaches, rising adoption of biosimilars in rheumatology, increasing investment in research and development, integration of digital health technologies, and regulatory approvals for novel therapies. Major trends in the forecast period include growth in telemedicine and remote monitoring solutions, expansion of targeted therapies for specific rheumatic conditions, emphasis on patient-centric care models, expansion of biologic treatments beyond monoclonal antibodies, and adoption of value-based pricing models.

The rising prevalence of autoimmune diseases is expected to propel the growth of the rheumatology therapeutics market going forward. An autoimmune disease is a condition where the immune system mistakenly attacks and damages the body's tissues. The prevalence of autoimmune diseases is growing due to a combination of genetic, environmental, and lifestyle factors, including increased awareness and improved diagnostic capabilities. Rheumatology therapeutics are required for autoimmune diseases to manage inflammation, alleviate symptoms, and prevent joint and tissue damage caused by the immune system attacking the body. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, around 514,000 people in Australia, or 2.0% of the population, were estimated to be living with rheumatoid arthritis in 2022. Rheumatoid arthritis accounted for 2.0% of the total disease burden and 16% of the burden for all musculoskeletal conditions in 2023. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the rheumatology therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables): https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Major companies operating in the rheumatology therapeutics market are developing innovative solutions, such as intravenous (IV) formulations, to enhance treatment efficacy and patient convenience. An intravenous (IV) formulation refers to a medication or substance that is administered directly into a vein through a needle or catheter. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Cosentyx, an intravenous (IV) formulation. This form of Cosentyx is uniquely approved to treat adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It works by specifically targeting and inhibiting interleukin-17A (IL-17A) and is the only non-tumor necrosis factor alpha (TNF-α) IV treatment available for these conditions.

The rheumatology therapeutics market report table of contents includes:

1. Executive Summary

2. Rheumatology Therapeutics Market Characteristics

3. Rheumatology Therapeutics Market Trends And Strategies

4. Rheumatology Therapeutics Market - Macro Economic Scenario

5. Global Rheumatology Therapeutics Market Size and Growth ...........

32. Global Rheumatology Therapeutics Market Competitive Benchmarking

33. Global Rheumatology Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Rheumatology Therapeutics Market

35. Rheumatology Therapeutics Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[adityarana1687-blog]

India Single-use Bioprocessing Probes And Sensors Market To Reach $191.0 Million By 2030

The India single-use bioprocessing probes and sensors market is anticipated to reach USD 191.0 million by 2030 and is anticipated to grow at a CAGR of 12.61% during the forecast period from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals and the growing popularity of disposable systems in preclinical trials are key factors driving the growth of the single-use bioprocessing probes and sensors market in India. The need for faster and more efficient drug development processes and the rising demand for personalized medicines contribute to the increased implementation of single-use bioprocessing systems.

The implementation of single-use technology (SUT) in biomanufacturing processes offers advantages such as reduced risk of cross-contamination and ensuring product purity and integrity, which is crucial for the growing domestic biosimilars and biologics market. It enhances operational efficiency, leading to shorter turnaround times and increased productivity - a key benefit for Indian manufacturers to scale and meet the rising domestic and global demand for biopharmaceuticals.

Furthermore, the commercial advantages of single-use sensors, such as streamlined operations, enhanced flexibility, and improved regulatory compliance and product quality, make them an attractive option for Indian biomanufacturers. The adoption of these technologies can help Indian companies lower their capital expenditure and achieve faster turnaround times.

Request a free sample copy or view report summary: India Single-use Bioprocessing Probes And Sensors Market Report

India Single-use Bioprocessing Probes And Sensors Market Report Highlights

The pH sensors type segment held the largest revenue share of 20.24% in 2023 and is expected to grow at the fastest CAGR over the forecast period. The growing demand for precise process monitoring, driven by the expanding biopharmaceutical industry, drives the adoption of single-use pH sensors. The oxygen sensors segment is expected to register a significant CAGR over the forecast period.

The upstream segment dominated the segment with a market share of 73.49% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. It is driven by the increasing demand for biopharmaceuticals and the need for efficient and cost-effective manufacturing processes.

The biopharmaceutical & pharmaceutical companies dominated the segment with a market share of 41.69% in 2023. The consistent introduction of new and innovative single-use bioprocessing probes and sensors is a key driver behind the growth of this market segment.

India Single-use Bioprocessing Probes And Sensors Market Segmentation

Grand View Research has segmented the India single-use bioprocessing probes and sensors market based on type, workflow, and end use:

India Single-use Bioprocessing Probes And Sensors Type Outlook (Revenue, USD Million, 2018 - 2030)

pH Sensor

Oxygen Sensors

Pressure Sensors

Temperature Sensors

Conductivity Sensors

Flow Meter & Sensors

Other Sensors

India Single-use Bioprocessing Probes And Sensors Workflow Outlook (Revenue, USD Million, 2018 - 2030)

Upstream

pH Sensor

Oxygen Sensors

Pressure Sensors

Temperature Sensors

Conductivity Sensors

Flow Meter & Sensors

Other Sensors

Downstream

pH Sensor

Pressure Sensors

Temperature Sensors

Conductivity Sensors

Flow Meter & Sensors

Other Sensors

India Single-use Bioprocessing Probes And Sensors End-use Outlook (Revenue, USD Million, 2018 - 2030)

Biopharmaceutical & Pharmaceutical Companies

CROs & CMOs

Academic & Research Institutes

Others

List of Key Players in theIndia Single-use Bioprocessing Probes And Sensors Market

Thermo Fisher Scientific

Sartorius AG

PreSens Precision Sensing GmbH

Hamilton Company

Mettler-Toledo India Private Limited

PARKER HANNIFIN CORP

Danaher

Saint-Gobain

[healthcareanna]

Biosimilars Market Size, Trends, Growth Analysis 2032

Biosimilars Market Overview

An integral component of the Biosimilars Market is the emergence of follow-on biologics. These biologics, which closely resemble existing biologic drugs, offer additional options for patients and healthcare providers. Follow-on biologics undergo rigorous testing to demonstrate similarity to the reference product, ensuring interchangeability and therapeutic equivalence. With their introduction, follow-on biologics stimulate competition in the biopharmaceutical industry, driving down prices and promoting innovation. As the demand for cost-effective biologic therapies continues to grow, the Biosimilars Market stands to benefit from the availability and acceptance of follow-on biologics, expanding treatment options and improving patient outcomes.

According to Market Research Future (MRFR), the biosimilars market insights was valued at USD 29.7 billion in 2023 and is projected to grow from USD 36.79 Billion in 2024 to USD 161.95 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.35% during the forecast period (2024 - 2032).

Biosimilars Market: Latest News and Developments

The FDA has approved the first Humira biosimilar. Adalimumab-bwwd (Cyltezo), a Humira biosimilar, received FDA approval in January 2023 for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Rising use of biosimilars in the treatment of cancer. A growing number of biosimilars are being used to treat cancer. The FDA authorised filgrastim-sndz (Zarxio), pegfilgrastim-jmdb (Onpro), and trastuzumab-dkst (Herzuma) as three biosimilars for the treatment of cancer in 2022.

Market Segmentation

Biosimilars industry can be considered with respect to product, applications, and end users.

The products based on which the market has been split into are recombinant glycosylated proteins, recombinant peptides, and recombinant non-glycosylated proteins. Recombinant non-glycosylated proteins are the biggest segment in the global market, thanks to the soaring cases of chronic disorders ranging from growth hormone deficiency to diabetes. As a result, recombinant non-glycosylated proteins are therapeutically used as they are readily available and are cost-effective.

Application-wise, the biosimilars market caters to chronic diseases, oncology, blood disorders, autoimmune diseases, infectious diseases, growth hormone deficiency, and more. Blood disorders have emerged as the top segment, as a result of the rising burden of the condition worldwide and the increased use of biosimilars by virtue of their low cost and the overall reduction in the treatment cost.

Major end users in the global market are hospitals and clinics as well as research institutes. Hospital and clinics are healthcare settings where treatment options and skilled professionals are easily available, and therefore, have emerged as the leading segment in the global industry.

Regional Status

Europe, MEA or Middle East & Africa along with the Americas, APAC or Asia Pacific are the primary markets for biosimilars.

Europe has taken the lead in the global market, as the region houses a vast elderly pool, with close to one fifth of the overall EU population aged more than 65 years. This has given way to several lifestyle-related disorders such as oncology, autoimmune diseases, diabetes, to name a few. Presumably, the scenario has raised the demand for biosimilars and can mean higher market growth over the next few years. In addition to this, numerous blockbuster biologics are on track to lose patent in the coming years, which should present lucrative opportunities to the biosimilar manufacturers.

The North American market displays a bright outlook and can emerge quite lucrative in the coming years, in view of the surging burden of chronic ailments in Canada and the United States. The rising spending on research activities by the healthcare agencies also fuels the market expansion in the region. Favorable reimbursement landscape in the region, especially in the US, encourages healthy competition as it results in lower incentives for the players to compete based on price.

The APAC market is slated to witness considerable growth, with China, South Korea and India offering a host of lucrative opportunities for drug development as well as commercialization. These are generics-driven countries and are known for frequently launching new and advanced manufacturing platforms, which has brought down the costs associated with biosimilar production. In the coming few years, majority of the patent expiries is touted to be in biosimilars, which is deemed as a profitable aspect by leading manufacturers and can translate into substantial market growth.

Eminent Vendors

Top global key players listed by biosimilars market outlook report include Stada Arzneimittel AG (Germany), Teva Pharmaceuticals (Israel), Biocon (India), Pfizer (US), Sandoz International (Germany), Eli Lily & Company (US), Actavis, Inc. (US), Dr. Reddy’s Laboratories (India), Cipla Ltd (India), Amgen, Inc. (US), Samsung Biologics (South Korea), Hospira Inc.(US), Mylan, Inc.(US), Celltrion (South Korea), to mention a few.

More Related Trending Topics

Medical Foods market

Insomnia market

Blockchain Technology in Healthcare market

Drug Device Combination market

Prefilled Syringes market

[tmr-blogs2]

Cardiovascular Drugs Market Size & Share to Surpass USD 195.6 billion By 2031

The global cardiovascular drugs market was valued at US$ 142.8 billion in 2022. The market is expected to expand at a CAGR of 3.8% from 2023 to 2031, reaching US$ 195.6 billion. Cardiovascular treatments may become more targeted and effective with genomics and personalized medicine advances. By identifying a patient's genetic profile and specific risks, tailored treatment can help improve outcomes and reduce side effects.

Researchers are working on new drug classes and therapies to treat cardiovascular disease, like gene therapies, RNA-based therapeutics, and stem cell therapies. By using these innovations, traditional medications could be rendered less effective and less durable. With digital health technologies like wearables and remote monitoring, cardio conditions could be better managed. Monitoring in real-time, coupled with data analytics, could lead to more proactive and personalized interventions.

Download Sample PDF of this Strategic Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33281

Research may continue into combinations of drugs with complementary mechanisms. The use of combination therapies may lead to better patient compliance and efficacy for cardiovascular diseases. Biosimilar versions may become more competitive as some cardiovascular drugs' patents expire. As a result, essential medications may be more affordable and easier to access.

Key Findings of the Market Report

Based on drug class, the anti-clotting agents (anti-coagulants and platelet aggregation inhibitors) will drive the cardiovascular drugs market.

North America accounts for the majority of market share as cardiovascular disease incidence rises.

Based on indication, the hypertension segment is anticipated to drive demand for cardiovascular drugs.

In terms of distribution channels, hospital pharmacy is expected to drive the market for cardiovascular drugs.

Global Cardiovascular Drugs Market: Regional Landscape

Cardiovascular drugs are expected to be in high demand in North America. North America continues to experience a significant burden of cardiovascular diseases (CVDs), accounting for a significant share of the overall burden of disease. Several cardiovascular diseases, including hypertension and coronary artery disease, are prevalent, resulting in a high demand for cardiovascular drugs.

Healthcare expenditures in North America are relatively high in the United States and Canada. This financial commitment to healthcare infrastructure and services enhances access to and utilization of cardiovascular drugs.

Pharmaceutics research and development are centered in North America, especially in the United States. Technological advances and drug discovery have introduced innovative cardiovascular drugs with improved efficacy and safety. In general, cardiovascular health is becoming more widely known among the public, which has led to a greater emphasis on prevention and early intervention.

Government regulatory agencies, such as Health Canada and the U.S. Food and Drug Administration (FDA), ensure cardiovascular medication safety and efficacy by overseeing drug approvals. Regulatory frameworks and government policies influence market dynamics.

Global Cardiovascular Drugs Market: Key Players

Leading companies follow market trends and launch generic heart failure drugs after patents on well-known drugs expire, per the latest cardiovascular drugs market analysis. In addition, the major drug manufacturers have established partnerships with academic institutions to develop innovative treatments and retain their competitive edge.

● ICU Medical Inc.

● Tandem Diabetes Care Inc.

● Medtronic plc

● Terumo Corporation

● F. Hoffmann-La Roche AG

● Baxter International

● BD

● Fresenius Kabi AG

● B. Braun SE

● Insulet Corporation

Key Developments

In January 2023, Lupin launched an India-based generic version of a Novartis drug for heart failure following the expiration of the patents on Valsartan and Sacubitril. In addition, it is available under the brand names Arnipin and Valentas, both of which are used for treating heart failure.

In January 2023, Glenmark Pharmaceuticals launched sacubitril + valsartan tablets for treating heart failure in India. The products are marketed as 'Sacu V'.

Global Cardiovascular Drugs Market: Segmentation

By Drug Class

Renin-Angiotensin System Blockers (ACE Inhibitors and Angiotensin Receptor Blockers)

Beta Blockers

Diuretics

Anti-Clotting Agents (Anti-Coagulants and Platelet Aggregation Inhibitors)

Antihyperlipidemics

Other Antihypertensive

Calcium Channel Blockers

Others

By Indication

Hypertension

Hyperlipidemia

Coronary Artery Disease

Peripheral Artery Disease

Arrhythmia

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Region

North America

Europe

Asia Pacific

Latin America

MEA

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=33281&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. 

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com  

[healthcaremarketanalysis]

Global Humanized Mouse and Rat Model Market worth $349 million by 2028 |

Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models.

Attractive Opportunities in humanized mouse and rat model Market

Download an Illustrative overview:

The North American market is projected to contribute the largest share for the humanized mouse and rat model industry

The global humanized mouse and rat model market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for humanized mouse and rat model market in 2022, while Europe is the second-largest market. US has emerged as the key revenue contributor to this region. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth. According to the American Cancer Society, over 1.9 million new cancer cases will be diagnosed in the US in 2023.

Humanized Mouse and Rat Model Market Dynamics:

Drivers:

Increasing research activities using humanized models

Rising demand for personalized medicine

Continuous support and initiatives from government and private sectors for cancer research

Growing R&D activities in pharmaceutical and biotechnology sectors

Restraints:

High cost of custom humanized models

Laws and regulations for ethical use of animal models in research

Opportunities:

Rising demand for humanized PDX models

Emergence of CRISPR as a powerful tool in biomedical research

Rising demand for humanized rat models

Challenges:

Alternatives for animal testing

Limitations of humanized mouse models

Key Market Players:

The prominent players in the global humanized mouse and rat model market include Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Inotiv (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), TRANS GENIC (Japan), Harbour Antibodies BV (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure services (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US).

Humanized Mouse and Rat Model Industry Advantages:

Predictive Validity: Humanized models closely mimic human physiology, genetics, and immune responses, providing a more accurate representation of human disease progression and treatment outcomes. This predictive validity enhances the reliability of preclinical data and improves the likelihood of successful translation to clinical trials.

Reduced Ethical Concerns: Using humanized models reduces the need for animal testing on non-human species, addressing ethical concerns and promoting more humane research practices.

Personalized Medicine: These models can be customized to replicate specific patient profiles or disease conditions, enabling personalized medicine approaches for tailored treatment strategies.

Drug Efficacy and Safety Screening: Humanized models allow for rigorous assessment of drug efficacy and safety before progressing to human clinical trials, reducing the risk of adverse effects and optimizing the drug development process.

Understanding Disease Mechanisms: By closely resembling human biology, these models offer valuable insights into disease mechanisms and underlying molecular pathways, advancing our understanding of complex diseases.

Rapid and Cost-Effective Research: Humanized models can accelerate research timelines by providing faster results compared to traditional animal models. This efficiency reduces overall research costs and expedites the discovery of novel therapies.

Translatability to Humans: The ability of humanized models to recapitulate human responses enhances the likelihood of successful translation of research findings to human patients, fostering more effective treatments.

Targeted Therapies: Humanized models facilitate the evaluation of targeted therapies by replicating the specific molecular targets present in human diseases, aiding in the development of precision medicine approaches.

Infectious Disease Research: Humanized models are particularly valuable in studying infectious diseases, allowing researchers to study pathogen-host interactions and test potential vaccines and antiviral treatments.

Academic and Industry Collaboration: The widespread adoption of humanized models fosters collaboration between academic institutions, pharmaceutical companies, and biotech firms, encouraging a dynamic exchange of knowledge and resources to advance medical research collectively.

Overall, the humanized mouse and rat model market represents a pivotal advancement in the biomedical field, enabling researchers to overcome the limitations of traditional models and paving the way for more effective and personalized medical interventions in the future.

[health-views-updates]

Single-Use Bioreactors Market Forecast: Key Insights and Future Outlook

Single-Use Bioreactors Market Outlook, Scope & Overview:

Industry reports indicate that the global single-use bioreactors market was valued at USD 3,872.40 million in 2023 and is projected to reach USD 13,784.83 million by 2031, growing at a CAGR of 17.2% over the forecast period 2024-2031.

Technological Advancements to Drive Growth of Global Single-Use Bioreactors Market

The adoption of single-use bioreactors (SUBs) will continue to influence global market revenues. Biopharmaceutical companies and research institutions are increasingly utilizing SUBs to enhance production efficiency, reduce contamination risks, and lower manufacturing costs.

As a product segment, SUBs currently hold a significant share of the global bioprocessing market. This segment is anticipated to grow at a year-over-year rate of 17.2% in 2024 over 2023 and reach USD 13,784.83 million in revenues by 2031. The increasing demand for biologics and biosimilars, coupled with advancements in cell culture technologies, is expected to drive market growth.

Single-Use Bioreactors – Market Dynamics

Drivers:

Single-use bioreactors are witnessing significant growth in the global market due to their ability to provide flexibility, scalability, and cost-effectiveness in biopharmaceutical production. The growing focus on reducing the risk of cross-contamination, the need for efficient process development, and the increasing adoption of disposable technologies in bioprocessing are key factors driving the adoption of SUBs worldwide. Additionally, the rising demand for personalized medicine and regenerative therapies is further propelling market growth.

Restraints:

Despite the growth potential, challenges such as high initial costs, concerns about the environmental impact of disposable systems, and the need for robust validation processes are hindering the widespread adoption of single-use bioreactors. Moreover, the limitations in handling large-scale production and the technical challenges associated with integrating SUBs into existing bioprocessing workflows pose additional challenges to market expansion.

Single-Use Bioreactors – Market Outlook

The proven benefits of single-use bioreactors in enhancing production efficiency, reducing operational costs, and improving process control have contributed to the market's growth. SUBs are expected to witness increased adoption across major biopharmaceutical markets, including North America, Europe, and Asia Pacific, driven by advancements in biotechnology and the growing focus on bioprocess optimization.

Global Single-Use Bioreactors Market

The rise in demand for single-use bioreactors in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global SUB market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of single-use bioreactors, supported by favorable regulatory frameworks and increasing investments in biopharmaceutical manufacturing.

Key Players in the Single-Use Bioreactors Market

Leading companies in the single-use bioreactors market include Thermo Fisher Scientific, Sartorius AG, Danaher Corporation, and Merck KGaA. These companies are at the forefront of developing and commercializing advanced single-use bioreactor systems for various bioprocessing applications, including cell culture, fermentation, and vaccine production.

In conclusion, the global single-use bioreactors market is poised for substantial growth over the forecast period, driven by technological advancements, increasing demand for biologics, and the expanding adoption of disposable bioprocessing solutions in biopharmaceutical production.

Other Trending Reports

Antibiotics Market Share by Company

Healthcare Business Intelligence (BI) Market Share by Company

Clinical Trial Imaging Market Share by Company

Proteomics Market Share by Company

[wellnessweb]

Overview of Microbial Fermentation Techniques

The Microbial Fermentation Technology Market size was estimated at USD 30,964.20 million in 2022 and is expected to reach USD 48980.988 million by 2030 with a growing CAGR of 5.9% during the forecast period of 2023-2030.The global Microbial Fermentation Technology Market  study includes a full analysis of key driving drivers, as well as profiles of prominent firms, essential product features, sales rates, and contact information. A thorough assessment of the most important market trends is also included in the research. Information is gathered through focus groups, surveys, interviews, a geographical and national study, and a comprehensive all-dimensional examination.

Major market factors such as drivers, constraints, opportunities, and threats are examined, as well as how they influence the market. External threats and opportunities have underlying drivers and limits in the global market. Strategic alliances, new product launches, initiatives, transactions, joint activities, and information on top market rivals are all covered by Microbial Fermentation Technology Market  research, as well as development factors, limits, and opportunities.

Get Sample Report @ https://www.snsinsider.com/sample-request/3814

Market Segmentation

By Application

Antibiotics

Probiotics Supplements

Monoclonal Antibodies

Recombinant Proteins

Biosimilars

Vaccine

Enzymes

Small Molecules

Others

By End User

Bio-Pharmaceutical Companies

Contract Research Organizations (CROs)

CMOs & CDMOs

Academic & Research Institutes

The global Microbial Fermentation Technology Market  analysis summary provides an overview of the topic, including definitions, classifications, applications, and the industrial chain structure. Global business research is offered for emerging markets, including competitive landscape studies and development trends.

Russia-Ukraine War Impact on Microbial Fermentation Technology Market

The impact of the Russia-Ukraine conflict on the worldwide market is detailed in the research paper. While tensions between Russia and Ukraine have been increasing for years, the present military action heightens fears of a long-term conflict within Ukraine, as well as market and global economic implications.

Competitive Scenario

The market report also includes a comprehensive library of future market estimates based on historical data. Customers can get quantitative industry expertise by looking at the most recent market data. The study investigates a variety of significant elements that influence firm players, including as suppliers, end-users, dealers, and others, in order to assist them in strategizing investment and pursuing various Microbial Fermentation Technology Market  growth chances. All significant competitors, prices, and positioning, as well as a thorough data collecting strategy, must operate in the same territory.

Report Highlights

Give an overview of the present situation of the target industry, including applications and innovations.

A comprehensive analysis of the Microbial Fermentation Technology Market 's situation amid COVID-19 pandemic and Russia-Ukraine War.

A detailed market analysis, including upstream raw materials, downstream output, and recent growth estimates.

Report Conclusion

The most recent Microbial Fermentation Technology Market  study looks at the target market's latest influence. The article looks at how the corporate environment is always changing, as well as the short- and long-term implications.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in re framing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Nasal Drug Delivery Market Growth Drivers

DNA Synthesis Market Growth Drivers

Osteoporosis Treatment Market Growth Drivers

Immunomodulators Market Growth Drivers

Proteomics Market Growth Drivers

[kenresearch1]

Top 5 players in US Biosimilar Market

Buy Now

STORY OUTLINE

Pfizer: Excelling in the line of Biosimilar drugs with an experience of more than 10 years with presence in over 180 countries.

Amgen: Making pharmaceutical products with an experience of over 40 years and presence in over 100 countries.

Viartis: Presence in over 165 countries, and making Biosimilar drugs in over 75 markets, this pharmaceutical company is another leading contributor of US Biosimilar market.

Coherus Biosciences: Increasing patient access to cost effective medicines with a Biosimilar drugs experience of 13 years.

Biogen: serving humanity through science with a experiences of more than 40 years in the field of biologics.

According to Ken Research, the US Biosimilar market is anticipated to grow at a CAGR of ~40% in the next five years which currently has a market size of ~USD 9.4 Bn.

The US Biosimilar market is rapidly growing and will be witnessing a significant growth in the next five years.

There are various reasons behind the rapid growth of US Biosimilar market. Some of the major reasons behind the growth of US Biosimilar market include the cost effective nature of Biosimilar drugs, rising geriatric population, rising prevalence of chronic diseases, and growing partnerships between companies to develop Biosimilar drugs.

Various companies and players are contributing to their best efforts in the growth of the US Biosimilar market.

This article aims to put light on the contributions done by the major players towards the growth of the US Biosimilar market.

1.Pfizer

Click to read more about Pfizer

Pfizer is a leading American pharmaceutical company which is operating in the field of generics or original drugs for more than 30 years. But did you know that this pharma not only manufactures biologics but also biosimilar drugs?

Pfizer has been in the business of biosimilar drugs for more than 10 years and have been quite successful as well. With more than 83,000 employees and presence in over 180 countries, this leading pharmaceutical company made almost USD 2 Bn. revenue only from its Biosimilar drugs sale in 2021.

Recently, this pharmaceutical company also collaborated with Samsung in two deals to produce various biosimilar drugs in South Korea. The deal size between these two companies happens to be approximately USD 900 Bn.

The major Biosimilar drugs of this pharmaceutical giant are primarily

ZIRABEV (a Biosimilar of Avastin)

TRAZIMERA (a Biosimilar of Herceptin)

RUXIENCE (a Biosimilar of Rituxan)

RITACRIT (a Biosimilar of Epogen)

NVYEPRIA (a Biosimilar of Neulasta)

NIVESTYM (a Biosimilar of Neupogen)

FILGRASTIM (a Biosimilar of Neupogen).

2.Amgen

Click here to Download a Sample Report

Amgen is another leading American pharmaceutical company which not only makes Biologics or generic drugs but also Biosimilar drugs. This pharmaceutical company has more than 40 years of experience when it comes to pharmaceutical line.

With over 25000 employees and presence in over 100 countries, this pharmaceutical company earned about USD 2 Bn. from their three biosimilar drugs which are reportedly MVASI, KANJITNTI, and AMJEVITA.

This pharma giant has also invested about USD 2 Bn. in the development of Biosimilar drugs.

This pharmaceutical company has made Biosimilar drugs primarily in 4 fields which are General Medicine, Oncology, and Hematology along with, Inflammation.

EPOTEIN ALFA

AMJEVITA

AVSOLA

KANJINTI

MVASI

RIABNI

are the various Biosimilar drugs of Amgen. And, STELARA, EYLEA, SOLIRIS are in their pipeline.

Recently Amgen revealed their Biosimilar report’s 8 version. It revealed a major information which said that the pharmaceutical company saved about USD 10 Bn. through their Biosimilar drugs in the past five years.

3.Viartis

Headquartered in Canonsburg, Pennsylvania, this American pharmaceutical company was founded only in 2020 yet they have achieved massive success in the pharmaceutical products with their revenue being USD 16 ~Bn. in 2022.

With presence in 165 countries and with over 45,000 employees worldwide, this pharmaceutical company makes pharmaceutical products in 10 areas which primarily are Cardiovascular, Dermatology, ophthalmology, Oncology, Gastroenterology, Women’s health, Infectious diseases, Diabetes & Metabolism, Immunology, CNS & Anesthesiology, Respiratory diseases and allergy.

Speaking of their first Biosimilar products, their first ever Biosimilar drug was launched in 2014. They have a variety of Biosimilar drugs which are primarily

TRASTUZUMAB

INSULIN ASPART

PEGFILGRASTIM

INSULIN GLARGINE-YFGN

ADALIMUMAB

BEVACIZUMAB

Their Biosimilar drug Insulin Glargine which is known as SEMGLEE was the first ever interchangeable Biosimilar drug in the United States which was FDA approved.

Their PEGFILGRASTIM also was the first ever FDA approved drug in the United States. They have launched their Biosimilar drugs in over 75 markets worldwide.

4.Coherus Biosciences:

Click here to Ask for a Custom Report

Headquartered in Redwood city, California this American pharmaceutical company earned a revenue of almost USD 211 Mn. In 2022.

With presence in over 55 countries and 300+ employees worldwide, this pharmaceutical company makes products in various areas such as solid tumors, non-small lung cancers, nasopharyngeal carcinoma, small cell lung cancer and hepatocellular carcinoma.

Speaking of their Biosimilar drugs, this pharma has been in the field of creating Biosimilar drugs since 2010 which has given them almost 13 years of experience.

This pharmaceutical company also disclosed that it plans to spend at least USD 1 Tn. on medicines worldwide, out of which at least 40% will be spent on Biosimilar drugs.

Their three major Biosimilar drugs which are also FDA approved include UDENCYA, YUSIMRY, and CIMERLI.

Udencya is a Biosimilar drug of Pegfilgrastim, Yusimry is a Biosimilar drug of Ranibizumab, and Cimerli is a Biosimilar drug of Adalimumab.

5.Biogen

Headquartered in Cambridge, Massachusetts, this American pharmaceutical company earned a revenue of around USD 10 Bn. in 2022.

This company happens to have an experience of more than 40 years when it comes to making pharmaceutical products.

With presence in over 80 countries and more than 9000 employees worldwide, this pharmaceutical company primarily deals in Neurology, Specialized Immunology, Neuropsychiatry, Ophthalmology, and Rare Diseases.

ADUCANUMAB

LECANEMAB

TOFERSEN

ZURANOLONE

LITIFILIMAB

BENAPALI

FLIXABI

IMRALDI

are some of their Biosimilar drugs.

With their Biosimilar drugs, more than 250,000 people have gone on Anti-Tumor Necrosis Factor therapy.

Recently, this pharmaceutical company also made an agreement with Bio-Thera solutions to develop a Biosimilar drug for the treatment of Rheumatoid Arthritis.

[creative-news-alert]

The Cell Therapy Manufacturing Market Is Estimated To Witness High Growth Owing To Advancement In Biologics And Biosimilar Therapeutics

The cell therapy manufacturing market is estimated to be valued at US$ 12.99 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Cell therapy involves using human cells to treat diseases. It holds potential in treatment of various diseases like cancer, neurological disorders, and cardiovascular illnesses. The market is growing due to advancement in regenerative medicines using stem cells, CAR T-cell therapy, and gene therapy vectors. Market Dynamics: The growth of the market is attributed to two key drivers - first, increasing demand for cell therapies due to rising prevalence of chronic diseases and need for effective therapeutics. Cell therapies have shown promise in treatments of cancer, diabetes, and neurological conditions. Second, advancement in bioprocessing technologies enable efficient manufacturing of cell therapies at lower costs. Continuous bioreactors, cell cloning techniques, and process automation have improved manufacturing efficiency and yield. However, high initial costs and regulatory risks are some challenges for the market. Stringent regulations for product approval also increase clinical trial timelines and costs. SWOT Analysis Strength: - Cell therapy manufacturing market size is growing rapidly due to increasing adoption of regenerative medicines and growing cancer research. - Advancements in cell culturing technologies and automated manufacturing processes help improve production efficiency and quality. - Increasing investments from key players to develop innovative cell therapies. Weakness: - High costs associated with cell therapy development and manufacturing makes it inaccessible for many patients. - Stringent regulatory processes increase development timelines and costs of new cell therapies. Opportunity: - Growing elderly population and incidence of chronic diseases drive the demand for cell therapy products. - Collaboration between academic research institutes and industry helps expedite clinical translation of cell therapies. Threats: - Limited donation of adult stem cells restrains the supply of raw materials. - Manufacturing complexities associated with maintaining cell viability and functionality. Key Takeaways The global cell therapy manufacturing market is expected to witness high growth, exhibiting CAGR of 15% over the forecast period, due to increasing research on stem cell therapy and personalized medicines. The market size is projected to reach US$ 12.99 Bn by 2023 from US$ 99.2 Mn in 2020. Regional analysis: North America dominates the global market due to presence of leading market players and growing funding for cell-based research in the US. Asia Pacific exhibits the fastest growth due to rising healthcare spending, developing research infrastructure and increasing patient population. Key players: Key players operating in the cell therapy manufacturing market are WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc. These players are focusing on new product launches, expansions and partnerships to strengthen their market position.

Get more insights on this topic: https://www.newswirestats.com/cell-therapy-manufacturing-market-size-and-outlook/ Explore more information, Please visit:https://www.newsintv.com/news/offshore-the-decommissioning-a-best-growing-sector/

[analyticalmarketresearch]

"

NA & EU Glove Liners Market Size, Trends and Growth opportunity, By Type (Sterile, Non-Sterile), By Material Type (Latex, Nylon, Polyester, Wool, Cotton, Others), By End User (Medical & Healthcare (Hospitals & Clinics, Ambulatory and Surgical Centers), Cleanroom Industry (Standard/Drywall Cleanrooms, Hardwall Cleanrooms, Softwall Cleanrooms), Pharmaceutical (Contract research and manufacturing services (CRAMS), Active pharmaceutical ingredients (APIs), Formulations, Biologics and biosimilars, Vaccines), Others (Academic and Research institutes, Electronics and Manufacturing)), Regional Outlook, Competitive Market Share & Forecast, 2023 – 2030.

NA & EU Glove Liners Market

The NA & EU Glove Liners Market was valued at USD 11,656.22 million in 2022 and is expected to reach USD 32,941 million by 2030 at a CAGR of 12.47% from 2023-2030. Glove liners are thin work gloves which are usually worn inside other mitts and gloves to provide an extra layer of protection, absorb sweat, and increase warmth. Liner glove works the same way as any insulation. Liners trap body heat and help one maintain warmth. The body heat warms the air, and this warm air gets trapped between the fibres of the liner, so the temperature of hand will be warmer by a few degrees.

Request Sample Link: https://analyticalmr.com/request-sample/NA-EU-Glove-Liners-Market/request-sample

Market Drivers

The manufacturing, automotive, chemical, and electronics industries are all sizable in both the US and the EU. These professions frequently entail using equipment, chemicals, or sharp objects, all of which put workers' hands at risk. Glove liners with cut-resistant or chemical resistance provide an additional layer of protection, lowering the risk of injuries and boosting their use in these industries. Glove liners are being used more frequently in the healthcare sector to shield workers from contact with germs and other pollutants. Glove liners are projected to become more popular as the healthcare sector expands. Personal protection equipment (PPE) is required under strict safety standards in many areas, including manufacturing, construction, healthcare, and oil and gas, in both the NA and the EU. To improve comfort and hygiene, glove liners are frequently used as an additional layer of protection underneath gloves. Glove liners are frequently in demand because of the execution of these requirements. Glove liners are essential for providing insulation and warmth in areas with cold weather, such as parts of the EU and NA. Glove liners are essential for protecting workers' hands from cold temperatures in sectors including outdoor construction, logistics and transportation. The demand for glove liners is further fuelled in these areas by leisure pursuits including skiing, snowboarding, and mountaineering.

Explore more information here: https://analyticalmr.com/reports-details/NA-EU-Glove-Liners-Market

Market Restraints

The usage of materials and chemicals in gloves is governed by strict laws in the NA and EU. When it comes to choosing materials, following manufacturing procedures, and fulfilling performance standards, compliance with these laws can be difficult for glove lining makers. Recent increases in the price of raw materials like latex and nitrile have put strain on glove liner producers' capacity to remain profitable. Additionally, there may be fierce pricing rivalry in the market, which puts downward pressure on the profit margins for glove liner makers. Customers that are price-sensitive could choose cost over quality, making it difficult for businesses to keep their profits high. The glove lining market in North America and Europe may be comparatively developed and saturated. It is vital for businesses to differentiate themselves through product innovation and high quality because this saturation may limit the growth potential for both new entrants and established firms. Glove liners can be replaced with a variety of products on the market, including disposable gloves or speciality gloves with built-in liners. These alternatives could have distinct advantages in some applications, which would be difficult for typical glove liners to develop around. The glove lining market may be impacted by rising environmental consciousness and laws governing sustainability and waste management. Creating environmentally friendly products, managing trash, and achieving sustainability goals may provide obstacles for businesses.

Impact Of COVID-19 On Market

The COVID-19 pandemic has raised demand for PPE, including glove liners. Gloves have been mandated for healthcare professionals and other vital employees to protect them from the infection. Glove liners, which are utilised to give a cosier and tighter fit, are becoming more and more popular because of this. Governments and regulatory agencies established stronger safety laws and guidelines in reaction to the pandemic. The usage of PPE, particularly glove liners, was emphasized by these laws across a range of industries. Glove liners are increasingly in demand because of the necessity for businesses to comply with these rules. During the pandemic, there was a rise in both awareness of and demand for glove liners, which sparked industry growth and innovation. Manufacturers concentrated on creating modern glove liners that were more breathable, comfortable, and had antibacterial qualities. To address the changing needs of end consumers, the market saw the introduction of new materials and technologies. The global supply chain for glove liners was disrupted by lockdowns, travel restrictions, and diminished manufacturing capacities. These interruptions resulted in manufacturing delays, raw material shortages, and difficulties obtaining critical components, affecting the availability of glove liners in the North American and European markets.

Impact of Russia-Ukraine Conflict on NA & EU Glove Liners Market

Nitrile, a crucial substance used in glove liners, is produced in large quantities in Russia and Ukraine. Prices have increased because of the fighting and supply chain disruptions. As a result, there is a decline in demand for glove liners in the NA and EU. A few businesses have moved their nitrile sourcing from Russia and Ukraine to other nations, such China, because of the unrest. As a result, lead times have gotten longer, and prices have gone up. Latex and neoprene are two materials that some businesses are looking to replace nitrile with. This is since nitrile is a petroleum-based commodity, and the conflict has raised questions about the availability of petroleum-based goods. Trade routes between Russia and Ukraine can be hampered by heightened tensions. This can affect the timely delivery of glove liners to the NA and EU markets by changing the transportation and logistics networks. It might be necessary to construct alternate trade channels, which would increase expenses and possibly cause delays. Russia may face trade restrictions or penalties from nations in the NA and the EU in response to the crisis. The availability of glove liners made in Russia in the NA and EU markets could be restricted, opening opportunities for domestic or alternative providers. These actions could also include taxes or import bans on certain commodities, including glove liners.

Market Segmentation

The NA & EU Glove Liners Market is segmented into Type, Material Type, and End User.

Regional Analysis

The NA & EU Glove Liners Market is segmented into countries such as USA, Canada, Mexico, Germany, France, UK, Russia, Italy, Spain, and Rest of Europe.

  The U.S accounted for higher market share of 42.26% in 2022, as it holds the largest market owing to the rising awareness of hygiene among healthcare professionals & growing number of admissions in hospitals. An increasing number of surgical operations using latex gloves are a high-impact rendering driver. Europe is anticipated to witness a significant demand in the forecast years. This market's expansion can be attributed to large presence of market players combined with high expenditures on medical healthcare advancements, increase in medical tourism, implementation of stringent regulations toward control of cross-contamination in hospitals, and enhanced distribution & supply within Europe.

Key Players

Various key players are discussed into the NA & EU Glove Liners Market Report including: Tenacious Holdings, Inc., MCR Safety, Lakeland Inc., Shamrock Manufacturing Co. Inc., VIP GLOVE SDN BHD, Midas Safety, Superior Glove, Hartalega Holdings, Rubberex Corporation (M) Berhad, and 3M.

Market Taxonomy

By Type • Sterile • Non-Sterile By Material Type • Latex • Nylon • Polyester • Wool • Cotton • Others By End User • Medical & Healthcare o Hospitals & Clinics o Ambulatory and Surgical Centers • Cleanroom Industry o Standard/Drywall Cleanrooms o Hardwall Cleanrooms o Softwall Cleanrooms • Pharmaceutical o Contract research and manufacturing services (CRAMS) o Active pharmaceutical ingredients (APIs) o Formulations o Biologics and biosimilars o Vaccines • Others o Academic and Research institutes o Electronics and Manufacturing By Region • North America o U.S. o Canada o Mexico • Europe o Germany o France o UK o Russia o Italy o Spain o Rest of Europe

"

[rohans18]

Polycythemia Vera Treatment Market Market Trends, Share, Competitive Dynamics, Demand - Forecast 2028

Global Polycythemia Vera Treatment Market, By Disease Type (Primary PV, Secondary PV), Treatment (Phelebotomy and Drug Therapy), Drug Type (Biologics and BioSimilars), Population Type (Children and Adults), Drugs Type (First Line Drug and Second Line Drugs), Route of Administration (Oral and  Parenteral), End User (Hospitals, Specialty Clinics,  Diagnostic Centers, Research Institute, and Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa), Industry Trends and Forecast to 2028

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Polycythemia Vera Treatment Market marketing report. The report has a lot to offer to both established and new players in the Polycythemia Vera Treatment Market industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Polycythemia Vera Treatment Market market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

The major players operating in the polycythemia vera treatment market report are ANP Technologies, INC., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Galena Biopharma, Inc., Gilead Sciences, Inc, Italfarmaco S.P.A., Karus Therapeutics Limited, Miragen Therapeutics, Inc.,Zydus Cadila Incyte Corp., Otsuka America Pharmaceutical, Inc. Pharmaclon, Teva Pharmaceuticals Inc., Schering-Plough, GNC Vector,  Alfarm among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-polycythemia-vera-treatment-market

With the help of credible Polycythemia Vera Treatment Market market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Polycythemia Vera Treatment Market market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Polycythemia Vera Treatment Market Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[healthcaremarketfmi]

Chromatography Resin Market In-Depth Analysis with Booming Trends Supporting Growth and Forecast 2023 to 2033

ESOMAR-certified consulting firm Future Market Insights’ report projects the global chromatography resin market to rise at an impressive pace between 2021 and 2031. Growing adoption of affinity chromatography resin technology is expected to increase the demand of chromatography resins across the globe. Alongside this, increase in demand for monoclonal antibody production will improve the sales over the coming years.

Demand for chromatography resins is rising extensively within the biopharmaceutical companies and research institutes. Burgeoning adoption of synthetic chromatography resin for the separation of biosimilars and development of monoclonal antibodies will spur the growth.

As per the FMI’s analysis, affinity chromatography resin sales are set to grow at over 11.3% CAGR, to surpass a valuation of approx. US$ 879.6 Mn by 2031-end. However, stringent regulatory policies, availability of cost-effective alternatives, and high cost of the chromatography technologies are some of the factors limiting the market growth.

Get Latest Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1349

Increasing funding by governments and initiatives undertaken to curb the mortality rate due to non-communicable diseases will spur the adoption of chromatography resins across the globe. Also, increasing expenditure on the research & development of drug delivery among the industry giants will also boost the market demand.

According to the FMI’s analysis, the global chromatography resins market is anticipated to reach a valuation of nearly US$ 2215 Mn, registering a steady growth at 6.90% CAGR between 2021 and 2031.

“Increasing research & development activities aimed at the development of economic monoclonal antibody drugs within the biopharmaceutical companies are expected to provide lucrative opportunities for the market players,” says the FMI analyst. 

Competitive Landscape

Agilent Technologies, Bio-Rad Laboratories Inc., GE Healthcare, Waters Corporation, Expedeon Ltd., Thermo Fisher Scientific Inc., Pall Corporation, Merck KGaA, PerkinElmer Inc., Kaneka Corporation, Shimadzu Corporation, Knauer GmbH, Tosoch Bioscience, Avantor Performance Materials Inc., Mitsubishi Chemical Corporation, W.R. Grace & Co., JSR Micro Inc., and Life Technology Corporation among others are some key players operating in the chromatography resin market.

As per the FMI’s analysis, the market is dominated by top 5 players in the global chromatography resin market, accounting for over 70% of market share. Top 5 players include Bio-Rad Laboratories, Inc., GE Healthcare, Tosoh Corporation, Merck KGaA, and Thermo Fisher Scientific Inc.

Market players operating in chromatography resins market are also forming tie-ups and targeted mergers & collaboration with other top healthcare companies for the expansion of their product portfolios.

For instance, in February 2021, Repligen Corporation, a global life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH, a prominent protein engineering company specializing in novel affinity ligand development, announced the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin used in the purification of COVID-19 vaccines.

On February 4th, 2021 Avitide, another leading player, finalized the development of an affinity bioprocess resin, AVIPure-COV2S, for the purification of recombinant COVID-19 vaccines.

 Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1349

More Insights on the Global Chromatography Resin Market

In its latest report, FMI provides an incisive coverage on the global chromatography resin market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (native and synthetic), technology type (affinity chromatography, anion exchange chromatography, cation exchange chromatography, size exclusion, and hydrophobic interaction), end user type (biopharmaceutical companies, clinical research organizations, and academic institutes), and across major regions (North America, Latin America, Eastern Europe, Asia Pacific excluding Japan, Western Europe, Japan and Middle East & Africa)

Chromatography Resin Market by Category

By Product Type:

Native

Synthetic

By Technology Type:

Affinity Chromatography

Anion Exchange Chromatography

Cation Exchange Chromatography

Size Exclusion

Hydrophobic Interaction

By End User Type:

Biopharmaceutical Companies

Clinical Research Organizations

Academic Institutes

[healthcaremarketanalysis]

Global Humanized Mouse and Rat Model Market worth $349 million by 2028

Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models.

Download an Illustrative overview:

Browse in-depth TOC on "Humanized Mouse and Rat Model Market"

140 - Tables

27 - Figures

188 – Pages

The genetic models dominated the humanized mouse and rat model market in 2022.

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. The genetic models generated highest revenue in 2022. In genetic humanized mouse models, the human protein/domain is expressed while the mouse protein/domain is suppressed in all cells and tissues. Genetic humanized mouse models have been successfully adopted in analyzing biological efficacy, safety testing, pharmaceutical compounds, and studying novel therapeutics. Humanized mouse models are gaining demand in studies around drug metabolism and immune system development & functioning.

The oncology segment represented a dominant share in the market in 2022.

Based on application, the humanized mouse and rat model market is segmented into toxicology, oncology, immunology and infectious diseases, hematopoiesis, neuroscience, and other applications. Humanized models mimic human cancers and act as essential platforms for cancer research. Cancer research involves studying cancer biology and understanding or predicting cancer, including tumor characterization, tumorigenesis, and metastasis. The growth of this segment can be attributed to the growing number of cancer research programs in academic & research institutes and favorable support by governments for cancer research.

The North American market is projected to contribute the largest share for the humanized mouse and rat model industry

The global humanized mouse and rat model market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for humanized mouse and rat model market in 2022, while Europe is the second-largest market. US has emerged as the key revenue contributor to this region. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth. According to the American Cancer Society, over 1.9 million new cancer cases will be diagnosed in the US in 2023.

Request 10% Customization:

Humanized Mouse and Rat Model Market Dynamics:

Drivers:

Increasing research activities using humanized models

Rising demand for personalized medicine

Continuous support and initiatives from government and private sectors for cancer research

Growing R&D activities in pharmaceutical and biotechnology sectors

Restraints:

High cost of custom humanized models

Laws and regulations for ethical use of animal models in research

Opportunities:

Rising demand for humanized PDX models

Emergence of CRISPR as a powerful tool in biomedical research

Rising demand for humanized rat models

Challenges:

Alternatives for animal testing

Limitations of humanized mouse models

Key Market Players:

The prominent players in the global humanized mouse and rat model market include Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Inotiv (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), TRANS GENIC (Japan), Harbour Antibodies BV (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure services (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US).

CHARLES RIVER LABORATORIES (US)

Charles River Laboratories (US) ranks second in terms of market position, attributive to its established range of mice models and rat models in the market. CRL is operational since more than 70 years, and has achieved core competency in vivo biology. The company provides early-stage drug discovery and preclinical development solutions, including  humanized mouse models. Its robust portfolio helps the company to strengthen collaboration with clients—from early lead generation to candidate selection. CRL’s portfolio is inclusive of around 150 different stocks and strains of animal models, the company is engaged in producing and selling the most widely used rodent research model strains and purpose-bred rats and mice. Charles River also provides a variety of related services that are designed to support clients in the use of research models in drug discovery and development.

INOTIV (US)

Inotiv is one of the leading market players in the mice model market. The strength of the company can be attributed to its robust product portfolio as well as a number of acquisitions & partnerships that allows it to market its products worldwide. Inotiv also has a significant geographical footprint in developed countries across North America and Europe. Inotiv entered the mice model market with the acquisition of Envigo. Since this strategic development, the company has worked towards improving its production & distribution capabilities. The company’s revenue grew to USD 547.7 million during the fiscal year 2022 from USD 89.6 million during the fiscal year 2021.

Recent Developments:

In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.

In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.

In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.

In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.

Report Link: ( Humanized Mouse and Rat Model Market )

Humanized Mouse and Rat Model Market Advantages:

Predictive Validity: Humanized models closely mimic human physiology, genetics, and immune responses, providing a more accurate representation of human disease progression and treatment outcomes. This predictive validity enhances the reliability of preclinical data and improves the likelihood of successful translation to clinical trials.

Reduced Ethical Concerns: Using humanized models reduces the need for animal testing on non-human species, addressing ethical concerns and promoting more humane research practices.

Personalized Medicine: These models can be customized to replicate specific patient profiles or disease conditions, enabling personalized medicine approaches for tailored treatment strategies.

Drug Efficacy and Safety Screening: Humanized models allow for rigorous assessment of drug efficacy and safety before progressing to human clinical trials, reducing the risk of adverse effects and optimizing the drug development process.

Understanding Disease Mechanisms: By closely resembling human biology, these models offer valuable insights into disease mechanisms and underlying molecular pathways, advancing our understanding of complex diseases.

Rapid and Cost-Effective Research: Humanized models can accelerate research timelines by providing faster results compared to traditional animal models. This efficiency reduces overall research costs and expedites the discovery of novel therapies.

Translatability to Humans: The ability of humanized models to recapitulate human responses enhances the likelihood of successful translation of research findings to human patients, fostering more effective treatments.

Targeted Therapies: Humanized models facilitate the evaluation of targeted therapies by replicating the specific molecular targets present in human diseases, aiding in the development of precision medicine approaches.

Infectious Disease Research: Humanized models are particularly valuable in studying infectious diseases, allowing researchers to study pathogen-host interactions and test potential vaccines and antiviral treatments.

Academic and Industry Collaboration: The widespread adoption of humanized models fosters collaboration between academic institutions, pharmaceutical companies, and biotech firms, encouraging a dynamic exchange of knowledge and resources to advance medical research collectively.

Overall, the humanized mouse and rat model market represents a pivotal advancement in the biomedical field, enabling researchers to overcome the limitations of traditional models and paving the way for more effective and personalized medical interventions in the future.

[healthcare-domain]

Bioprocess Containers Market worth $9.6 billion by 2026 - Exclusive Report by MarketsandMarkets™

According to the new market research report "Bioprocess Containers Market by Type(2D and 3D Bags, Accessories), Application(Process development, Upstream and Downstream Process), End User(Pharma & Biopharma Companies, CMOs & CROs, Academic & Research Institute), & Region – Global Forecast to 2026", published by MarketsandMarkets™, the global Bioprocess Containers (BPCs) Market is projected to grow from USD 2.9 billion in 2021 to USD 9.6 billion by 2026, at a CAGR of 26.3% during the forecast period.

Browse in-depth TOC on "Bioprocess Containers"

248 – Tables 35 – Figures 216 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107645832

The Growth in the bioprocess containers market is mainly driven by factors such as the growing biologics market, affordability and sustainability of single-use bioprocess technologies, and rising biopharmaceutical R&D. Emerging countries and the patent expiry of biologics are expected to offer growth opportunities for players operating in the bioprocess containers (BPCs) market during the forecast period.

The 2D bioprocess containers segment accounted for the largest share of the type segment in the BPCs market in 2020.

On the basis of type, the bioprocess containers market is segmented into 2D bioprocess containers, 3D bioprocess containers, and other containers and accessories. In 2020, the 2D bioprocess containers segment accounted for the largest share of the market. 2D bioprocess containers are frequently used in cell harvesting and for the transportation of bulk drug products and bulk drug precursors.

The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the end user segment in the market in 2020.

On the basis of end user, the BPCs market is segmented into pharmaceutical & biopharmaceutical companies, CROs & CMOs, and academic & research institutes. In 2020, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the bioprocess containers market. The demand for biopharmaceuticals among the senior population is increasing as the elderly are more prone to various diseases/disorders that can be treated using biologics. This has resulted in the increasing focus of biopharmaceutical companies developing affordable biologics at lower costs. As bioprocess containers have wide applications in research & process development, the adoption of BPCs is increasing with the growth in the development and manufacturing of biologics and biosimilars.

The Asia Pacific region is the fastest-growing region of the bioprocess containers market in 2020.

In 2020, the Asia Pacific region accounted for the fasted growing region of the BPCs market. Factors such as the growing biopharmaceuticals industry, increasing life science research, rising investments by pharmaceutical and biotechnology companies and key players in the region, and the growing number of CROs & CMOs in several APAC countries are contributing to the growth of this market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=107645832

Some of the leading players operating in the bioprocess containers market are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US),  Danaher Corporation (US), and Merck Millipore (Germany).